April 14, 2021
Business News

PureTech Founded Entity Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia


BOSTON–()–PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that results from the EMERGENT-1 Phase 2 clinical trial evaluating KarXT for the treatment of schizophrenia were published in the New England Journal of Medicine (NEJM).

The published manuscript titled…



Click here to view the original article.

Related Posts

You might also like ...

AON Splash Image
G42 Announces Investment by Silver Lake
The Equilar Diversity Network Welcomes New Partner Third Arrow Strategies Japan Board Diversity Network with a Focus on Increasing Board Gender Diversity in Japan
Samsung Introduces PixCell LED for Intelligent Headlight Systems to Enhance Road Safety